BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 23
• 26
• 27
• 28
• 29
• 30

• 

  Employer Resources

  Report: 2026 Employment Outlook

  BioSpace’s 2026 U.S. Life Sciences Employment Outlook examines the state of the biopharma workforce amid ongoing funding pressure, elevated layoffs and cautious hiring sentiment, while highlighting early signals of stabilization and cautious optimism for the year ahead.

  January 28, 2026

   · 

  1 min read

   · 

  BioSpace Insights
• 

  Career Advice

  Subtraction Before Addition: A Smarter Way To Set and Execute Goals

  If workloads aren’t adjusted as needed, the company’s priorities are already compromised. Executive coach Angela Justice explores what happens when goals move forward without removing unnecessary work and what to do about it.

  January 28, 2026

   · 

  6 min read

   · 

  Angela Justice
• 

  Podcast

  Roche Makes Obesity Splash, Moderna Cans Vaccine Trials, Sarepta’s New Data, More

  Roche’s obesity candidate achieves 22.5% weight loss in Phase II; Moderna pulls the plug on late-stage vaccine trials as Health Secretary Robert F. Kennedy’s anti-vaccine policies and rhetoric continues; and embattled gene therapy maker Sarepta announces new data in Duchenne muscular dystrophy.

  January 28, 2026

   · 

  1 min read

   · 

  Heather McKenzie
• 

  Cancer

  Cardiff Craters Amid Executive Exits, Mixed Mid-Stage Data

  Onvansertib cut the risk of death or disease progression by 62% versus standard of care, but analysts await more detailed data.

  January 28, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  gene therapy

  Advanced Therapies Week 2026: ‘Solving for Science’ and Weathering Global Complexity

  Phacilitate’s annual event dawns as cell and gene therapies reach a new tipping point: the science has hit new heights just as regulatory and government policies spark momentum and frustration.

  January 28, 2026

   · 

  4 min read

   · 

  Heather McKenzie
• 

  Cancer

  J&J’s Darzalex Faspro Notches Another Multiple Myeloma Indication, Pushing Into Frontline

  Darzalex Faspro, in combination with an anti-cancer triplet, is the first anti-CD38-based regimen for newly diagnosed patients with multiple myeloma, regardless of eligibility for stem cell transplantation.

  January 28, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Gene editing

  Lilly Leans Into Hearing Loss in $1.12B+ Gene Editing Pact With Seamless

  The deal will help bolster Eli Lilly’s growing hearing loss portfolio, which is anchored by the gene therapy AK-OTOF.

  January 28, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Manufacturing

  BMS-Partnered Cellares Raises $257M for Cell Therapy Manufacturing Expansion

  Cellares, which last year became the first company to receive the FDA’s new advanced manufacturing technology designation, expects to support clinical production this year and offer commercial-scale manufacturing services in 2027.

  January 28, 2026

   · 

  2 min read

   · 

  Nick Paul Taylor
• 

  Rare diseases

  REGENXBIO Delay Could Put Denali in Pole Position for Hunter Syndrome Approval

  The discovery of a tumor in a patient who received REGENXBIO’s gene therapy for Hurler syndrome prompted the FDA to place a hold on that program along with the company’s Hunter syndrome program, which is awaiting an FDA decision on or before Feb. 8.

  January 28, 2026

   · 

  2 min read

   · 

  Dan Samorodnitsky
• Press Releases

  Cytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

  January 28, 2026

   · 

  12 min read